Henry Skinner buys time in the fight against antimicrobial resistance; Vertex's Michael Parini becomes president and COO at Freeline while CFO Brian Silver plans his exit
When Henry Skinner was in charge of antibiotics-focused SelectX Pharmaceuticals about 15 years ago, the company had “very good science,” but couldn’t keep it capitalized …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
